Truist analyst Richard Newitter lowered the firm’s price target on Zimmer Biomet to $112 from $117 and keeps a Hold rating on the shares. The firm is adjusting its model to reflect the recent management commentary at investor conferences around ERP system disruptions that are expected to impact the company over the second half of 2024, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $115 from $120 at Canaccord
- Zimmer Biomet price target lowered to $110 from $112 at Wells Fargo
- Wolfe starts Zimmer Biomet at Peer Perform, sees $115-$130 fair value
- Zimmer Biomet initiated with a Peer Perform at Wolfe Research
- Zimmer Biomet guidance update an ‘unwelcome negative,’ says Truist